ABS-201

May 07, 2026 — Absci Corporation (Nasdaq: ABSI) reported business updates and first quarter fiscal 2026 financial/operating results, highlighting progress for ABS-201, an AI-designed long‑acting anti–prolactin receptor (PRLR) antibody in the Phase 1/2a HEADLINE trial for androgenetic alopecia (AGA). The company has dosed all four planned healthy-volunteer single ascending dose (SAD) cohorts; ABS-201 has been well tolerated with “favorable emerging” safety data. Preliminary pharmacokinetic modeling supports a targeted dosing interval of two to three injections over six months. Absci also initiated dosing in the first multiple ascending dose (MAD) cohort in AGA participants and expects preliminary safety/tolerability/PK data in Q2 2026, interim proof-of-concept data in H2 2026, and full proof-of-concept data in early 2027. Absci also plans to start a Phase 2 endometriosis trial for ABS-201 in Q4 2026 (potential proof-of-concept in H2 2027) and added ABS-202, a preclinical anti-PRLR antibody for an undisclosed inflammation/immunology indication.

Financially (quarter ended March 31, 2026): revenue $0.2M (vs $1.2M prior year), R&D $19.3M, SG&A $9.1M, net loss $29.6M, and cash/marketable securities $125.7M; runway projected into 1H 2028.